This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator.
Aims of Study: 1) To evaluate the presence of the systemic inflammatory marker hsCRP in osteoarthritis (OA) patients who have had a total hip arthroplasty (THA) compared to matched total hip arthroplasty OA-THA control patients who do not have periprosthetic osteolysis. 2) To evaluate the presence of elevated serum inflammatory markers (hsCRP, IL-1, IL-6, TNF-alpha) and pro-osteoclast signaling proteins (increased RANKL/OPG ratios) with the presence of osteolysis in OA-THA patients. compared to OA-THA, patients, compared to OA-THA controls who do not have osteolysis. 3) OA-THA patients with osteolysis have an absent of decreased history of bisphosphonate medication use than matched non-osteolytic OA-THA controls. 4) OA-THA patients with osteolysis have a history of an increased frequency and duration of high-impact activities such as running, jogging or walking, when compared to matched non-osteolytic OA-THA controls. Hypothesis: 1) Osteoarthritis (OA) patients who require THA revision due to periprosthetic osteolysis have evidence of systemic inflammation, evidence by elevated serum hsCRP levels, which is not present in matched OA-THA controls without osteolysis, or in OA THA patients undergoing hip revision surgery for reasons other than osteolysis. 2) Inflammatory mediators (hsCPR, IL-1, IL-6, TNF-alpha) and pro-osteoclast signaling proteins (increased RANKL: OPG ratios) are elevated in the sera of OA-THA patients with osteolysis, and are not elevated in OA-THA patients without osteolysis, or in OA-THA patients who require hip revision surgery for reasons other than osteolysis. 3) OA-THA patients with osteolysis have an absent or decreased history of bisphosphonate medication use than matched non-osteolytic OA-THA controls. 4) OA-THA patients with osteolysis have a history of an increased frequency and duration of high-impact activities such as running, jogging or walking, when compared to matched non-osteolytic OA-THA controls
Showing the most recent 10 out of 370 publications
